EP2307421A4 - oxindole - Google Patents

oxindole

Info

Publication number
EP2307421A4
EP2307421A4 EP09774383A EP09774383A EP2307421A4 EP 2307421 A4 EP2307421 A4 EP 2307421A4 EP 09774383 A EP09774383 A EP 09774383A EP 09774383 A EP09774383 A EP 09774383A EP 2307421 A4 EP2307421 A4 EP 2307421A4
Authority
EP
European Patent Office
Prior art keywords
oxindole compounds
oxindole
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09774383A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2307421A1 (en
Inventor
Mustapha Haddach
Johnny Yasuo Nagasawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of EP2307421A1 publication Critical patent/EP2307421A1/en
Publication of EP2307421A4 publication Critical patent/EP2307421A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP09774383A 2008-06-30 2009-06-30 oxindole Withdrawn EP2307421A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7709108P 2008-06-30 2008-06-30
US15642609P 2009-02-27 2009-02-27
US18009509P 2009-05-20 2009-05-20
PCT/US2009/049318 WO2010002933A1 (en) 2008-06-30 2009-06-30 Oxindole compounds

Publications (2)

Publication Number Publication Date
EP2307421A1 EP2307421A1 (en) 2011-04-13
EP2307421A4 true EP2307421A4 (en) 2011-07-13

Family

ID=41466309

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09774383A Withdrawn EP2307421A4 (en) 2008-06-30 2009-06-30 oxindole

Country Status (12)

Country Link
US (2) US8124649B2 (https=)
EP (1) EP2307421A4 (https=)
JP (1) JP2011526917A (https=)
KR (1) KR20110025996A (https=)
CN (1) CN102137866A (https=)
AU (1) AU2009267048A1 (https=)
BR (1) BRPI0914942A2 (https=)
CA (1) CA2729745A1 (https=)
IL (1) IL210355A0 (https=)
MX (1) MX2011000150A (https=)
WO (1) WO2010002933A1 (https=)
ZA (1) ZA201100539B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
CN102688234B (zh) * 2011-03-21 2015-07-29 华东理工大学 吲哚酮衍生物作为rsk2抑制剂的合成与应用
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
CN103509009A (zh) * 2012-06-21 2014-01-15 中国科学院上海药物研究所 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
PL3303330T3 (pl) 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3187496A1 (de) 2015-12-30 2017-07-05 Heliatek GmbH Verbindung für fotoaktive organische elektronische bauelemente und fotoaktives organisches elektronisches bauelement enthaltend die verbindung
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
WO2025085819A1 (en) * 2023-10-18 2025-04-24 Washington University Kinase inhibitor compositions and related methods for the treatment of a disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096361A2 (en) * 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
WO2005040116A2 (en) * 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
JP2007084494A (ja) * 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
JP3663382B2 (ja) * 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US8367664B2 (en) * 2006-01-24 2013-02-05 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
DK1973910T3 (da) 2006-01-27 2013-08-12 Shanghai Hengrui Pharm Co Ltd Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
WO2002096361A2 (en) * 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2005040116A2 (en) * 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
JP2007084494A (ja) * 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KOBAYASHI, MASANOBU ET AL: "Flavone derivatives as pim-1 activity inhibitors for treatment of cancer and other pim-1-related diseases", XP002639478, retrieved from STN Database accession no. 2007:376869 *
ISLAM ET AL: "Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 14, 19 June 2007 (2007-06-19), pages 3819 - 3825, XP022119961, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.05.060 *
JIANG T ET AL: "Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 8, 15 April 2006 (2006-04-15), pages 2109 - 2112, XP025106919, ISSN: 0960-894X, [retrieved on 20060415], DOI: 10.1016/J.BMCL.2006.01.066 *
See also references of WO2010002933A1 *
YAN, XIAO CHEN ET AL: "1-Acetyl-3,3-bis[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-indolin-2(3H)- one", ACTA CRYSTALLOGRAPHICA, SECTION E: STRUCTURE REPORTS ONLINE , E62(3), O917-O918 CODEN: ACSEBH; ISSN: 1600-5368 URL: HTTP://JOURNALS.IUCR.ORG/E/ISSUES/2006/03/00/CI6750/INDEX.HTML, 2006, XP008137159 *
YAN, XIAO CHEN ET AL: "1-Acetyl-3,3-bis[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-ylmethyl]indolin-2- one", ACTA CRYSTALLOGRAPHICA, SECTION E: STRUCTURE REPORTS ONLINE , E62(10), O4640-O4641 CODEN: ACSEBH; ISSN: 1600-5368 URL: HTTP://JOURNALS.IUCR.ORG/E/ISSUES/2006/10/00/HB2149/INDEX.HTML, 2006, XP008137161 *
YAN, XIAO CHEN ET AL: "1-Acetyl-3,3-bis[3-(4-methylphenyl)-1,2,4-oxadiazol-5-ylmethyl]-1H-indol- 2(3H)-one", ACTA CRYSTALLOGRAPHICA, SECTION E: STRUCTURE REPORTS ONLINE , E62(6), O2462-O2463 CODEN: ACSEBH; ISSN: 1600-5368 URL: HTTP://JOURNALS.IUCR.ORG/E/ISSUES/2006/06/00/BT2086/INDEX.HTML, 2006, XP008137162 *

Also Published As

Publication number Publication date
IL210355A0 (en) 2011-03-31
MX2011000150A (es) 2011-04-05
CN102137866A (zh) 2011-07-27
CA2729745A1 (en) 2010-01-07
US20100041635A1 (en) 2010-02-18
WO2010002933A1 (en) 2010-01-07
KR20110025996A (ko) 2011-03-14
JP2011526917A (ja) 2011-10-20
US20120190669A1 (en) 2012-07-26
ZA201100539B (en) 2011-11-30
US8124649B2 (en) 2012-02-28
AU2009267048A1 (en) 2010-01-07
EP2307421A1 (en) 2011-04-13
BRPI0914942A2 (pt) 2015-08-11

Similar Documents

Publication Publication Date Title
EP2307421A4 (en) oxindole
BRPI0922904A2 (pt) "compostos"
EP2491025A4 (en) AZAAZULENVERBINDUNGEN
EP2044055A4 (en) amide compounds
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
EP2211620A4 (en) THERAPEUTIC COMPOUNDS
BRPI0913806A2 (pt) "composição"
EP2280916A4 (en) HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
EP2291078A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
BRPI0914533A2 (pt) "métodos"
BRPI0818338A2 (pt) Composto de pirimidil indolina
EP2129224A4 (en) 5,6-dihydro-1H-pyridin-2-one compounds
EP2088861A4 (en) Benzimidazole compounds
MA30948B1 (fr) MYRTILLE NOMME " DrisBlueThree "
EP2035369A4 (en) THERAPEUTIC COMPOUNDS
EP2379510A4 (en) quinazolinone
MA30949B1 (fr) MYRTILLE NOMME "DrisBlueTwo"
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
EP2164324A4 (en) THERAPEUTIC COMPOUNDS
EP2321275A4 (en) CONNECTIONS AGAINST MALARIA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0491000000

Ipc: C07D0405060000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20110531BHEP

Ipc: A61K 31/404 20060101ALI20110531BHEP

Ipc: C07D 417/14 20060101ALI20110531BHEP

Ipc: C07D 405/14 20060101ALI20110531BHEP

Ipc: C07D 405/06 20060101AFI20110531BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110610

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAGASAWA, JOHNNY, YASUO

Inventor name: HADDACH, MUSTAPHA

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103